By inducing endogenous neuroprotection, hypoxic post-conditioning following stroke may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The investigators thus hypothesize that hypoxic post-conditioning represents a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. The investigators will further investigate the potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will also be investigated, based on biological and imagery markers.
Stroke is the second leading cause of death and the third leading cause of disability-adjusted life-years worldwide. If acute stroke therapy has decreased mortality, more than 50% of stroke survivors are left with sensorimotor and cognitive deficiencies. Recovery and rehabilitation treatments, aiming at inducing neuroplasticity, maximizing function in unaffected brain areas or implementing compensatory strategies to improve overall function, benefit from an extensive time window that ranges from days to months. Their development is urgently needed. Several endogenous neuroprotective mechanisms are spontaneously engaged following stroke to achieve neuroprotection and stimulate brain repairing processes. Conditioning the central nervous system can trigger endogenous mechanisms of neuroprotection. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism. While hypoxia is well recognized as a common underlying mechanism of many pathological conditions, experimental data indicate that exposure to specific doses of hypoxia (by breathing a hypoxic gas mixture) can be neuroprotective. Preconditioning is defined as the exposure to the conditioning stimulus before injury onset, to induce tolerance or resistance to the subsequent injury. Postconditioning refers to the application of the conditioning stimulus after injury or damage, to stimulate tissue reparation or neuroplasticity. As stroke is an unpredictable event, translating hypoxic preconditioning to clinical practice seems difficult. However, developing postconditioning strategies seems of clinical and rehabilitative relevance. Thus, an increase in neuronal salvage and neurogenesis, along with an increase in brain-derived neurotrophic factor expression and a reduced neuroinflammation were shown in murine models of hypoxic conditioning following ischemic stroke. By inducing endogenous neuroprotection, hypoxic conditioning may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The main working hypothesis is that hypoxic postconditioning may represent a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. All adverse events will be evaluated and quoted in accordance with National Institute of Health Common Criteria for Terminology for Adverse Events 5.0 (NIH CCTAE) recommendations, particularly with respect to Sub-sections "Cardiac disorders ", "Nervous system disorders" and "Vascular Disorders". Safety assessments will be performed every 48 hours, throughout the 8-week conditioning period, in addition to the conventional clinical follow-up performed in the rehabilitation unit. The potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition will also be further investigated. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will be investigated, based on biological (serum inflammatory markers, growth and neurogenesis biomarkers) and imagery markers (morphological MRI sequences, functional connectivity (resting state), and brain vascularization).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
Grenoble Aalpes University Hospital
Grenoble, Veuillez Sélectionner Une Région., France
Secondary adverse events
The safety of such a therapeutic strategy will be assessed by systematic screening for adverse events at each conditioning session and at follow-up visits throughout the duration of exposure (8 weeks) by a trained experimenter, blinded to the therapeutic intervention. All adverse events will be assessed and scored as a composite endpoint according to the NIH CCTAE 5.0 (National Institute of Health Common Terminology Criteria for Adverse Events), including in particular those listed in the sub-sections on "Cardiological Pathologies", "Central Nervous System Pathologies" and "Vascular Pathologies".
Time frame: Through study completion, an average of 8 weeks
Fugl-Meyer
Function - Fugl-Meyer motor function Score range: 0-100 Higher values indicate better performance. A score of 96-99 indicates light motor incoordination A score of 85-95 indicates hemiparesis A score ≤ 84 indicates hemiplegia
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
New Functional ambulation category (nFAC) score
Function - New Functional ambulation category (nFAC) score Score range: 0-5 A score of 0 indicates no functional ability to walk A score of 5 indicates independent walking
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Prospective collection of number of falls
Function - Prospective collection of number of falls
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Modified Rankin Scale (mRS)
Activity limitation - Modified Rankin Scale (mRS) Score range: 0-6 The mRS scores range from à (no symptom) to 6 (death)
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Barthel index
Activity limitation - Barthel index Score range: 0-100 The higher the score, the better the function and the independence
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
16-item Stroke Impact Scale
Participation The higher the score, the better the performance.
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
10-metre walk test
Mobility - Instrumented 10-metre walk test, carried out at spontaneous walking speed, 3 trials: collection of quantitative spatiotemporal step parameters and their variability, collection of walking speed.
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Timed-up and Go test
Mobility - Timed-up and Go test: 3 trials
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Montreal Cognitive Assessment
Neuropsychological assessment Score range: 0-30 Normal if \>26/30 The higher the score, the better the cognitive performance.
Time frame: Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Morphological sequences
The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. High-resolution anatomical sequences: T1, T2, FLAIR, for calculation of lesion volume and delineation of lesion mask.
Time frame: Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Diffusion and perfusion sequences
The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Bolus perfusion (gadolinium) T1 and Diffusion Tensor Imaging (DTI, 60 directions or High Angular Resolution Diffusion Imaging (HARDI)), allowing calculation of the Apparent Diffusion Coefficient (ADC) map.
Time frame: Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Cerebral blood flow
The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Cerebral vasoreactivity (to a hypercapnic stimulus) assessed by Arterial Spin Labelling (ASL) and Blood oxygenation level-dependent (BOLD) sequences.
Time frame: Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Resting state functional magnetic resonance imaging (fMRI)
The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Functional connectivity measurements.
Time frame: Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Cerebral Blood Flow
Cerebral blood flow will be assessed by measuring the flow velocity in the middle cerebral artery (MCAv), estimated by continuous measurement of the right middle cerebral artery using a 2 megahertz (MHz) pulsed transcranial Doppler (TCD) (MultiDop T, Compumedics Germany GmbH, Germany). Following standardized research techniques, the Doppler probe will be fixed to the temporal window with the aid of a helmet (DiaMon, Compumedics Germany GmbH) to maintain an optimal insonation position throughout the study and thus avoid any movement artifact.
Time frame: Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.